Literature DB >> 22905055

Outcome of ventilator-associated pneumonia: Impact of antibiotic therapy and other factors.

Noyal Mariya Joseph1, Sujatha Sistla, Tarun Kumar Dutta, Ashok Shankar Badhe, Desdemona Rasitha, Subhash Chandra Parija.   

Abstract

BACKGROUND: Ventilator-associated pneumonia (VAP) is the most frequent infection in patients intubated for longer than 48 hours. There is a great interest in determining the factors influencing the outcome of VAP, as it may help in reducing the associated morbidity and mortality. This study aimed to determine the impact of appropriate antibiotic therapy based on endotracheal aspirate cultures on the outcome of VAP. We have also studied the other factors that may influence the outcome of VAP.
METHOD: A cohort study was conducted in the intensive care units of a tertiary care hospital in South India over a period of 15 months. The outcome of VAP was assessed by prolongation of the duration of mechanical ventilation and/or death of the patient.
RESULTS: The duration of mechanical ventilation was significantly prolonged in patients with VAP (16.61 ± 8.2 d vs. 8.21 ± 5.9 d, P < 0.0001). VAP patients receiving partially or totally inappropriate therapy (defined as lack of coverage of one or all the significant VAP pathogens) were at significantly high risk for death (Relative risk, 2.00; 95% confidence interval, 1.14 to 3.52; P 0.0008). A delay of > 2 days in administering the first dose of appropriate antibiotic therapy significantly prolonged the duration of ventilation (P < 0.0001). Infection by multi-drug resistant pathogens, polymicrobial infection and time of onset of VAP did not have significant impact on the outcome of VAP.
CONCLUSION: Early administration of appropriate antibiotic therapy, based on the antibiogram of the VAP pathogens identified by quantitative culture of endotracheal aspirate, could lead to an improved outcome of patients with ventilator-associated pneumonia.

Entities:  

Keywords:  Ventilator-associated pneumonia; appropriate therapy; outcome; quantitative culture

Year:  2012        PMID: 22905055      PMCID: PMC3413931          DOI: 10.4066/AMJ.20121004

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  16 in total

1.  Diagnostic investigation of ventilator-associated pneumonia using bronchoalveolar lavage: comparative study with a postmortem lung biopsy.

Authors:  A B Balthazar; A Von Nowakonski; E M De Capitani; P V Bottini; R G Terzi; S Araújo
Journal:  Braz J Med Biol Res       Date:  2001-08       Impact factor: 2.590

2.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

Review 3.  Diagnosis and treatment of ventilator-associated pneumonia.

Authors:  Ilana Porzecanski; David L Bowton
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

4.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

5.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.

Authors:  Jordi Rello; Daniel A Ollendorf; Gerry Oster; Montserrat Vera-Llonch; Lisa Bellm; Rebecca Redman; Marin H Kollef
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

6.  Incidence and outcome of polymicrobial ventilator-associated pneumonia.

Authors:  Alain Combes; Corinne Figliolini; Jean-Louis Trouillet; Najibi Kassis; Michel Wolff; Claude Gibert; Jean Chastre
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

7.  Appropriateness and delay to initiate therapy in ventilator-associated pneumonia.

Authors:  C M Luna; P Aruj; M S Niederman; J Garzón; D Violi; A Prignoni; F Ríos; S Baquero; S Gando
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

8.  Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid.

Authors:  J Pugin; R Auckenthaler; N Mili; J P Janssens; P D Lew; P M Suter
Journal:  Am Rev Respir Dis       Date:  1991-05

Review 9.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

10.  Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia.

Authors:  Pieter O Depuydt; Dominique M Vandijck; Maarten A Bekaert; Johan M Decruyenaere; Stijn I Blot; Dirk P Vogelaers; Dominique D Benoit
Journal:  Crit Care       Date:  2008-11-17       Impact factor: 9.097

View more
  4 in total

1.  Mechanical ventilator as a major cause of infection and drug resistance in intensive care unit.

Authors:  Marwa M E Abd-Elmonsef; Dalia Elsharawy; Ayman S Abd-Elsalam
Journal:  Environ Sci Pollut Res Int       Date:  2017-02-23       Impact factor: 4.223

2.  Trends and Factors Associated With Ventilator-Associated Pneumonia: A National Perspective.

Authors:  Harshil Shah; Ahmed Ali; Achint A Patel; Vaidarshi Abbagoni; Ruchir Goswami; Ananth Kumar; Felipe Velasquez Botero; Elohor Otite; Hardik Tomar; Maheshkumar Desai; Prakash Maiyani; Hiteshkumar Devani; Faraz Siddiqui; Salman Muddassir
Journal:  Cureus       Date:  2022-03-29

3.  Clinical Features and Outcomes of Monobacterial and Polybacterial Episodes of Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii.

Authors:  Dalia Adukauskiene; Ausra Ciginskiene; Agne Adukauskaite; Despoina Koulenti; Jordi Rello
Journal:  Antibiotics (Basel)       Date:  2022-07-04

4.  Clinical characteristics and risk factors of polymicrobial Staphylococcus aureus bloodstream infections.

Authors:  Cheng Zheng; Shufang Zhang; Qingqing Chen; Li Zhong; Tiancha Huang; Xijiang Zhang; Kai Zhang; Hongwei Zhou; Jiachang Cai; Linlin Du; Changming Wang; Wei Cui; Gensheng Zhang
Journal:  Antimicrob Resist Infect Control       Date:  2020-05-27       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.